GLPG5101
Cell therapy
Evidence outlook · program status
Discontinued (2026-02-23), as a strategic decision by the sponsor
Galapagos (now Lakefront Biotherapeutics) wound down its cell therapy business after a strategic review and terminated the Phase 1/2 ATALANTA-1 study of GLPG5101 early. The trials below are preserved as the program's evidence history; no evidence signal is assigned to a program the sponsor has stopped.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
Atalanta-1 NCT06561425 · Non-Hodgkin Lymphoma Registry: NCT06561425 | 1/2 | Phase 1: Number of participants with adverse events (AEs) and serious adverse events (SAEs) (2 years); Phase 1: Number of participants with Dose-Limiting Toxicities (DLTs) (From first dose up to Day 28); Phase 2: Number of participants with objective response (OR) per the Lugano Classification or International Primary central nervous system lymphoma Collaborative Group (IPCG) criteria for PCNSL or per iwCLL (CLL [Cohort 8] and DLBCL-RT [Cohort 7] only) (2 years) 2026-05-27 | Phase 1 dose escalation: five dose-limiting toxicities, including one death from intra-abdominal haemorrhage. | not yet graded | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 1/2 (1)
What this study did
Competitive landscape
Other CD19 drugs
Inebilizumab, obecabtagene autoleucel, Tafasitamab, budoprutug, cemacabtagene ansegedleucel and 12 more. Compare all 18 CD19 drugs
This mechanism is crowded: 18 other tracked programmes target it, 17 of them ahead of this one.
This drug's own stage for Non-Hodgkin Lymphoma: Discontinued. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| GLPG5101: this drug | Discontinued | Cell therapy | CD19 | not yet graded | No reviewed efficacy summary in this indication | |
| Inebilizumab | Approved(overall) | Monoclonal antibody | CD19 | Reliable signal(overall) | No reviewed efficacy summary in this indication | |
| Obecabtagene Autoleucel (Aucatzyl) | Approved(overall) | Cell therapy | CD19 | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| PF-05280586 | Approved | Biologic (subtype unspecified) | CD20 | Reliable signal | NCT02213263: Overall Response Rate (ORR): Percentage of Participants With Overall Response (OR) at Week 26 (Week 26): Rituximab-EU 70.7 percentage of participants (95% CI 63.8 to 76.9) | PF-05280586 75.5 percentage of participants (95% CI 68.9 to 81.4) | |
| Rituximab-Abbs (Truxima) | Approved | Monoclonal antibody | CD20 | not yet graded | No reviewed efficacy summary in this indication | |
| Tafasitamab | Approved(overall) | Monoclonal antibody | CD19 | Reliable signal(overall) | No reviewed efficacy summary in this indication | |
| Obinutuzumab | Phase 3 | Monoclonal antibody | CD20 | not yet graded | No reviewed efficacy summary in this indication | |
| Budoprutug | Phase 2(overall) | Monoclonal antibody | CD19 | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| Cemacabtagene Ansegedleucel | Phase 2(overall) | Cell therapy | CD19 | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| FT819 | Phase 2(overall) | Cell therapy | CD19 | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| Rapcabtagene Autoleucel | Phase 2(overall) | Undisclosed | CD19 | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| Beijing Biotech Anti-CD19 CAR-T | Phase 1/2(overall) | Cell therapy | CD19 | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| Zugocabtagene Geleucel | Phase 1/2(overall) | Cell therapy | CD19 | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| ABBV-319 | Phase 1(overall) | Antibody–drug conjugate | CD19 | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| ABBV-519 | Phase 1(overall) | — | CD19 | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| Azercabtagene Zapreleucel | Phase 1(overall) | Cell therapy | CD19 | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| HRS-3738 | Phase 1 | Small molecule | Cereblon (CRBN) | not yet graded | No reviewed efficacy summary in this indication | |
| IC19 CAR-T | Phase 1(overall) | Cell therapy | CD19 | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| UTAA09 | Phase 1(overall) | Cell therapy | CD19 | Weak signal(overall) | No reviewed efficacy summary in this indication | |
| ZM001 | Phase 1(overall) | Cell therapy | CD19 | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| ABBV-619 | —(overall) | Undisclosed | CD19 | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| FT522 | —(overall) | Cell therapy | CD19 | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| Vispacabtagene Regedleucel | Discontinued | Cell therapy | CD19 | not yet graded(overall) | No reviewed efficacy summary in this indication |
Upcoming events
No upcoming readouts on record for this asset.